Amgen v Sanofi: Scotus grapples with enablement

The showdown between Amgen and Sanofi concerning the proper test for enablement under Section 112 of the US Patent Act has finally taken place at the US Supreme Court.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Sanofi wins enablement showdown at SCOTUS

18 May 2023 Case concerned the interpretation of a key requirement of the US Patent Act | Amgen’s ‘roadmap’ held to describe step-by-step its own trial-and-error method for finding functional antibodies.

Big Pharma

Amgen secures five-year ban on psoriasis drug copycat

20 April 2023 Court affirms decision that two Otezla patents are not invalid | Apremilast generics set for 2028 release.

Big Pharma

Don’t distort enablement law, Amgen tells SCOTUS

9 March 2023 Sanofi and Regeneron accused of wanting to change patent system | The US Supreme Court will decide whether a controversial court decision should stand.

More features

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Amgen v Sanofi: Scotus grapples with enablement

More on this story

Editor's picks

Editor's picks

More features